Autologous Stem Cell Transplant Clinical Trials

3 recruiting

Autologous Stem Cell Transplant Trials at a Glance

7 actively recruiting trials for autologous stem cell transplant are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Minneapolis, Augusta, and Edmonton. Lead sponsors running autologous stem cell transplant studies include Center for International Blood and Marrow Transplant Research, AHS Cancer Control Alberta, and Augusta University.

Browse autologous stem cell transplant trials by phase

Treatments under study

About Autologous Stem Cell Transplant Clinical Trials

Looking for clinical trials for Autologous Stem Cell Transplant? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Autologous Stem Cell Transplant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Autologous Stem Cell Transplant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

CIBMTR Research Database

Autologous Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research99,999,999 enrolled2 locationsNCT01166009
Recruiting
Phase 2

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin LymphomaAutologous Stem Cell Transplant
Masonic Cancer Center, University of Minnesota28 enrolled1 locationNCT06377540
Recruiting
Phase 2

High Heated Humidity in Stem Cell Transplant

Autologous Stem Cell Transplant
AHS Cancer Control Alberta90 enrolled1 locationNCT05358262
Recruiting
Phase 3

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

Multiple MyelomaAutologous Stem Cell Transplantation
Augusta University172 enrolled1 locationNCT06588413
Recruiting
Phase 2

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-CellAutologous Stem Cell Transplantation
The First Affiliated Hospital of Soochow University64 enrolled1 locationNCT06381830
Recruiting

Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Autologous Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research99,999,999 enrolled1 locationNCT04920474
Recruiting
Phase 2

A phase II study of lenalidomide and prednisolone as post-autologous stem cell transplant (ASCT) maintenance therapy for patients with Multiple Myeloma incorporating residual disease monitoring.

Residual Multiple Myeloma in patients post autologous stem cell transplant.
Malignant haematology and stem cell transplant Service40 enrolled1 locationACTRN12611000597998